Pathogenetic therapy of multiple sclerosis

Relevance. Multiple sclerosis is accompanied by rapid progression of the disease, the development of early disability and a violation of the patient's quality of life. In recent years, advances in understanding the etiology and pathogenesis of this disease have led to the expansion of therapeutic approaches, it has become possible to influence the course of the disease. Objective - to study the effectiveness of the use of drugs that change the course of multiple sclerosis in patients registered at the center of multiple sclerosis of the Udmurt Republic.

Materials and methods. The statistical analysis was performed on 45 patients of the neurological department of the "First Republican Clinical Hospital" of the Ministry of Health of the Udmurt Republic, diagnosed with multiple sclerosis, using immunomodulatory or immunosuppressive therapy.

Results. At the beginning of the study, the group of patients using immunomodulatory therapy included 31 patients (68.89 %), the group of immunosuppressors -14 patients (31.11 %). The average time from the onset of the disease to the start of therapy was 1.64 ± 5.71 months. 42 patients (93.33 %) out of 45 included in the study started therapy with an immunomodulator. The average time from the start of therapy to inclusion in the study was 113.00 ± 47.52 months in the immunomodulatory therapy group. 11 patients (78.57 %) out of 14 taking immunosuppressive therapy at the start of the study switched to it after previous immunomodulatory therapy. 3 patients (6.67 %) out of 45 included in the study started treatment with immunosuppressive therapy. In the immunosuppressive therapy group, the duration of treatment was 62.57 ± 74.52 months. Progression of the disease from the moment of initiation of therapy to inclusion in the study was observed in 19 patients - 42.22 %. An increase in the EDSS index was recorded by an average of 1.82 ± 0.31 points. Improvement of clinical condition was observed in 6 patients - 13.33 %. A decrease in the EDSS index was recorded by an average of 0.91 ± 0.22 points. The difference in the EDSS index in the groups of immunomodulators and immunosuppressors is insignificant. There was no dependence of the patient's clinical condition on the number and activity of foci of demyelination.

Conclusions. The objective clinical condition of the patient has no significant difference in the groups of immunomodulatory and immunosuppressive therapy, which suggests that the correct selection of a particular drug by the attending physician and its constant use by the patient is important in order to reduce the risks of complications, slow down the progression of the disease and preserve the quality of life of the patient.

1. Boyko A.N., Khachanova N.V., Melnikov M.V., Sivertseva S.A., Evdoshenko E.P., Spirin N.N., etc. New directions of immunocorrection in multiple sclerosis. Journal of Neurology and Psychiatry named after S.S. Korsakov. 2020;120(2):103–109. (In Russ).

2. Zavalishin I.A., Eliseeva D.D. Treatment of multiple sclerosis. Doktor. Ru. 2009;4:25-29. (In Russ)].

3. Gusev E.I., Boyko A.N., Stolyarov I.D. Multiple sclerosis. Reference book of terms. 2nd ed., add. and izm. M.: Human health. 2015:436. (In Russ)].

4. Sorensen P.S., Blinkenberg M. The potential role of ocrelizumab in the treatment of multiple sclerosis: current data and prospects for the future. Therapeutic advances in neurological disorders. 2016;9(1):44–52. (In Russ)].

5. Lee R., Patterson K.R., Bar-Or A. Reassessment of the contribution of B cells in multiple sclerosis. Natural immunology. 2018;19(7):696–707. (In Russ).

6. Sabatino J. J. Jr., Forgave A.K., Declared S.S. B cells in autoimmune and neurodegenerative diseases of the central nervous system. Nature Neuroscience reviews. 2019;20(12):728–745. (In Russ).

7. Hu Y, Turner MJ, Shields J, Gale MS, Hutto E, Roberts BL, Siders WM, Kaplan JM. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009;128(2):260–270.

8. Baker D, Herrod SS, Alvarez-Gonzalez C, Zalewski L, Albor C, Schmierer K. Both cladribine and alemtuzumab may effect MS via B-cell depletion. Neurol Neuroimmunol Neuroinflammation. 2017;4(4):360.

9. Stolyarov I.D., Petrov A.M., Votintseva M.V., Ivashkova E.V. Gilenia: new opportunities in the treatment of multiple sclerosis. The Medical Council 2011;9-10:108-111. (In Russ)].

10. Koppas L., Boyko A.N. The use of tablet preparations for the treatment of multiple sclerosis: the current state of the problem. Journal of Neurology and Psychiatry named after C.C. Korsakov. 2014;114(2-2):63–71. (In Russ).

11. Kawasaki H, Carrera CJ, Piro LD, et al. Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood. 1993 Feb 1;81(3):597–601.